| 08.00 - 08.30 | Registration, networking, refreshments |
|
|
Welcome address Caroline Rynn (Roche UK) and Heide Duevel (Merck KGaA Darmstadt) |
| 09.00 - 10.30 |
ADME session 1: Covering multiparameter ADME optimisation of TPDs and
practical in vitro & in vivo challenges encountered Andy Pike (AZ UK), Stefan Steyn (Pfizer US), Ed Hooper-Greenhill (GSK UK) |
| 10.30 - 11.00 | Break/networking |
| 11.00 - 12.00 |
ADME session 2: Covering PBPK of TPDs and novel delivery approaches to
target the site of action Farzaneh Salem (GSK UK), Donglu Zhang (Genentech US) |
| 12.00 - 13.00 | Buffet lunch/networking |
| 13.00 - 14.30 |
PKPD session: Covering PKPD properties of TPDs and application of
integrated modeling frameworks to quantitatively predict full in vivo
degradation profiles James Yates (GSK UK), Sofia Guzzetti (AZ UK), Andreas Reichel (Bayer DE) |
| 14.30 - 15.00 | Break/networking |
| 15.00 - 15.30 |
ADME/PKPD round table Q&A All main presenters |
| 15.30 - 16.30 |
Spotlight talks: Covering computational frameworks to identify the key
drivers of efficacy, a mechanistic PK/PD modeling framework case
example, IVIVE of TPD clearance, and prediction of IMHB-mediated PROTAC
chameleonicity Uddipan Sarma (UCB UK), Christine K. Maurer (Merck KGaA Darmstadt), Robin Haid (Bayer DE) and Diego Garcia Jimenez (Uni Turin Italy) |
| 16.30 - 17.00 |
Meeting highlights and future perspectives Caroline Rynn (Roche UK) and Heide Duevel (Merck KGaA Darmstadt) |
| 17.00 | Meeting closes |